All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 119 of 206 pages ‹ First < 117 118 119 120 121 > Last ›
HSL5306
Davis D.
Continuing education, guideline implementation, and the emerging transdisciplinary field of knowledge translation.
J Contin Educ Health Prof 2006 Win 01;26:(1):5-12
http://www3.interscience.wiley.com/cgi-bin/abstract/112549279/ABSTRACT?CRETRY=1&SRETRY=0
HSL19039
Woloshin S, Schwartz LM
What's the rush? The dissemination and adoption of preliminary research results.
J Natl Cancer Inst 2006 15;98:(6):372-3
http://jnci.oxfordjournals.org/content/98/6/372.long
HSL4607
Doherty S.
Evidence-based implementation of evidence-based guidelines.
Int J Health Care Qual Assur Inc Leadersh Health Serv 2006;19:(1):32-41
HSL4633
Seeman N, Brown AD.
Remembering Peter Drucker: inspiring the quality revolution in healthcare.
Healthc Q 2006;9:(1):50-2,
HSL4708
Caplovitz A
Turning Medicine Into Snake Oil: How Pharmaceutical Marketers put Patients at Risk
Trenton NJ: NJPIRG Law and Policy Center 2006
http://njpirg.org/reports/TurningMedintoSnakeOil.pdf
HSL4844
Loken B.
Consumer psychology: categorization, inferences, affect, and persuasion.
Annu Rev Psychol 2006;57:453-85
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4487&uid=16318603&db=PubMed&url=http://dx.doi.org/10.1146/annurev.psych.57.102904.190136
HSL4845
Crano WD, Prislin R.
Attitudes and persuasion.
Annu Rev Psychol 2006;57:345-74
http://arjournals.annualreviews.org/doi/abs/10.1146/annurev.psych.57.102904.190034
HSL4849
Wogart JP, Calcagnotto G.
Brazil's fight against AIDS and its implications for global health governance.
Healthc Q 2006;9:(1):76-89
HSL4881
Horejsi J.
[Do you know what you are reading?]
Cas Lek Cesk 2006;145:(2):163-4
HSL4899
Hasman A, Holm S.
Direct-to-consumer advertising: should there be a free market in healthcare information?
Camb Q Healthc Ethics 2006 Win;15:(1):42-9
HSL4900
Dutta-Bergman MJ.
A formative approach to strategic message targeting through soap operas: using selective processing theories.
Health Commun 2006;19:(1):11-8
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=4487&uid=16519588&db=PubMed&url=http://dx.doi.org/10.1207/s15327027hc1901_2
HSL4922
Montori VM, Leung TW, Devereaux PJ, Schunemann HJ, Akl EA, Gafni A, Guyatt GH.
Can contraindications compromise evidence-based, patient-centered clinical practice?
Can J Clin Pharmacol 2006 Win;13:(1):e92-101
HSL4995
Boggs W.
Meeting presentations can influence treatment patterns
J Natl Cancer Inst 2006;98:372-373,382-388.
http://www.medscape.com/viewarticle/527662
HSL4998
Busfield J.
Pills, Power, People: Sociological Understandings of the Pharmaceutical Industry
2006;40:(2):297-314
http://soc.sagepub.com/cgi/content/abstract/40/2/297?etoc
HSL5054
Polimeni G, Salvo F, Cutroneo P, Morreale I, Patrizio Caputi A.
Adverse reactions induced by NSAIDs and antibacterials : analysis of spontaneous reports from the sicilian regional database.
Drug Saf 2006;29:(5):449-59
HSL5078
Lee R.
FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
J Law Med Ethics 2006 Spr;34:(1):131-4
HSL5196
Lough M.
What the educators are saying
BMJ 2006;332:(7555):1450
http://bmj.bmjjournals.com/cgi/content/short/332/7555/1450?etoc
HSL5387
Del Mar C
Clinical Thinking: Evidence, Communication and Decision-Making
London: BMJ Publishing 2006
HSL5416
Mitchell TB, Dyer KR, Peay ER.
Patient and physician characteristics in relation to clinical decision making in methadone maintenance treatment.
Subst Use Misuse 2006;41:(3):393-404
http://taylorandfrancis.metapress.com/(vd040writt1bijmrlvrij5qj)/app/home/contribution.asp?referrer=parent&backto=issue,9,11;journal,5,59;linkingpublicationresults,1:107866,1
HSL5437
Vernon JA, Johnson SJ, Hughen WK, Trujillo A.
Economic and developmental considerations for pharmacogenomic technology.
Pharmacoeconomics 2006;24:(4):335-43
HSL5438
Hughes D.
Rationing of drugs for rare diseases.
Pharmacoeconomics 2006;24:(4):315-6
HSL5543
Breggin PR
Court filing makes public my previously suppressed analysis of Paxil's effects.
Ethical Human Psychology and Psychiatry 2006 Spr;8:(1):77-84
http://www.springerpub.com/
HSL5553
Wakefield M, Durrant R.
Effects of exposure of youths at risk for smoking to television advertising for nicotine replacement therapy and Zyban: an experimental study.
Health Commun 2006;19:(3):253-8
http://www.leaonline.com/doi/abs/10.1207/s15327027hc1903_7
HSL5554
Campo S, Cameron KA.
Differential effects of exposure to social norms campaigns: a cause for concern.
Health Commun 2006;19:(3):209-19
http://www.leaonline.com/doi/abs/10.1207/s15327027hc1903_3
HSL5576
Greenhalgh T, Russell J.
Promoting the skills of knowledge translation in an online master of science course in primary health care.
J Contin Educ Health Prof 2006 Spr;26:(2):100-8
http://www3.interscience.wiley.com/cgi-bin/abstract/112660759/ABSTRACT?CRETRY=1&SRETRY=0
HSL5651
Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H, Kumar R.
Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.
J Pharm Pharm Sci 2006;9:(1):50-9
http://www.ualberta.ca/~csps/JPPS9(1)/Rohra.D/promotion.htm
HSL5752
Centre for science in the public interest
Ensuring Independence and Objectivity at The National Academies
Washington, DC: Centre for science in the public interest 2006
http://cspinet.org/new/pdf/nasreport.pdf
HSL5777
Skala N, Hellander I.
A review of data on the U.S. health sector: summer 2005.
Int J Health Serv 2006;36:(1):157-76
HSL5822
Evans BJ, Flockhart DA.
The unfinished business of U.S. drug safety regulation.
Food Drug Law J 2006;61:(1):45-63
HSL5927
Sharp RR, Yarborough M.
Informed trust and the financing of biomedical research.
J Law Med Ethics 2006 Sum;34:(2):460-4
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1748-720X.2006.00052.x
HSL5930
Vuorenkoski L.
[The case of rofecoxib(Vioxx)-what do we learn from this case].
Duodecim 2006;122:(4):385-6
HSL5951
Bayer erectile dysfunction drug found to breach
Choice : Australian Consumers' Association Date uncertain 2006
HSL5970
Lauer CD, Turp JC.
[Without risks and side effects? Product advertisements in dental journals]
Schweiz Monatsschr Zahnmed 2006;116:(7):718-24
HSL5978
Masereel B.
[Critical review of new chemical and biological molecules launched in Belgium during the period 2001-2005].
J Pharm Belg 2006;61:(2):45-57
HSL5989
Davenport J.
Is your advertising a liability risk?
J N J Dent Assoc 2006 Spr;77:(2):31
HSL5992
Dresser R.
Private-sector research ethics: marketing or good conflicts management The 2005 John J. Conley Lecture on Medical Ethics
Theor Med Bioeth. 2006;27(2):115-39 2006;27:(2):115-39
http://www.springerlink.com/content/bq855531108k52p6/
HSL5999
Kuczkowski KM.
Drug mislabeling erros in (obsteric) anaesthesia.
Acta Anaesthesiol Belg 2006;57:(1):57
HSL6000
Datti B, Carter MW.
The effect of direct-to-consumer advertising on prescription drug use by older adults.
Drugs Aging 2006;23:(1):71-81
HSL6073
Bradford WD, Kleit AN, Nietert PJ, Steyer T, McIlwain T, Ornstein S.
How Direct-To-Consumer Television Advertising For Osteoarthritis Drugs Affects Physicians' Prescribing Behavior.
Health Aff 2006 Sep-Oct;25:(5):1371-1377
http://content.healthaffairs.org/cgi/content/full/25/5/1371
HSL6080
Liebenberg W.
Another white lie?
J Esthet Restor Dent 2006;18:(3):155-60
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1708-8240.2006.00002.x
HSL6081
Manley PA.
Communicate first.
Mark Health Serv 2006 Sum;26:(2):42
HSL6082
Cho H, Salmon CT.
Fear appeals for individuals in different stages of change: intended and unintended effects and implications on public health campaigns.
Health Commun 2006;20:(1):91-9
http://www.leaonline.com/doi/abs/10.1207/s15327027hc2001_9
HSL6120
Manthei JR, Hathaway CR, Grant MA, Chung DD.
Merck v Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals.
Food Drug Law J 2006;61:(2):273-7
HSL6157
Hullett CR.
Using functional theory to promote HIV testing: the impact of value-expressive messages, uncertainty, and fear.
Health Commun 2006;20:(1):57-67
http://www.leaonline.com/doi/abs/10.1207/s15327027hc2001_6
HSL6158
Polonec LD, Major AM, Atwood LE.
Evaluating the believability and effectiveness of the social norms message 'most students drink 0 to 4 drinks when they party'.
Health Commun 2006;20:(1):23-34
http://www.leaonline.com/doi/abs/10.1207/s15327027hc2001_3
HSL6159
Smith SW, Atkin CK, Roznowski J.
Are 'drink responsibly' alcohol campaigns strategically ambiguous?
Health Commun 2006;20:(1):1-11
http://www.leaonline.com/doi/abs/10.1207/s15327027hc2001_1
HSL6161
Morgan MA, Dana J, Loewenstein G, Zinberg S.
Interactions of doctors with the pharmaceutical industry
J Med Ethics 2006;32:559-563
http://jme.bmjjournals.com/cgi/content/full/32/10/559
HSL6168
Koerselman GF.
[The importance of public-private cooperation. Comment on Vandereycken]
Tijdschr Psychiatr. 2006;48(2):131-3 2006;48:(2):131-3
HSL6169
Vandereycken W.
[Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry].
Tijdschr Psychiatr 2006;48:(2):119-29
HSL6170
Rubsaam J.
[Reaction to 'About the comparison of public-private cooperation'].
Tijdschr Psychiatr 2006;48:(4):343;
HSL6180
Sedgeworth J, Derewlany L.
Institution/investigator-initiated clinical trials in Canada.
Can J Clin Pharmacol 2006 Sum;13:(2):e236-9
HSL6181
Leo J.
The SSRI trials in children: disturbing implications for academic medicine.
Ethical Hum Psychol Psychiatry 2006 Spr;8:(1):29-41
HSL6186
FDA electronic drug labels to improve patient safety.
J Pain Palliat Care Pharmacother 2006;20:(2):96-7
HSL6195
Emami J.
In vitro - in vivo correlation: from theory to applications.
J Pharm Pharm Sci 2006;9:(2):169-89
http://www.ualberta.ca/~csps/JPPS9_2/Jaber_Emami/MS_190.htm
HSL6197
Edmunds-Ogbuokiri T.
Pharmacy. Update: Black box warnings for FDA-approved antiretrovirals.
HIV Clin 2006 Sum;18:(2):12-3
HSL6212
Arden JD, Brensilver PC.
A bitter pill for plaintiffs: obstacles to market theories of causation in prescription drug consumer fraud cases.
Food Drug Law J 2006;61:(3):539-46
HSL6216
Loucks MK.
Pros and cons of off-label promotion investigations and prosecutions.
Food Drug Law J 2006;61:(3):577-83
HSL6217
Vernon W.
The Canadian perspective: trends in drug and medical device class actions in Canada.
Food Drug Law J 2006;61:(3):569-76
HSL6218
Talati AR.
The Class Action Fairness Act of 2005: changing the class action landscape circuit by circuit.
Food Drug Law J 2006;61:(3):561-8
HSL6219
Roller ST, Voorhees T Jr, Lunkenheimer AK.
Obesity, food marketing and consumer litigation: threat or opportunity?
Food Drug Law J 2006;61:(3):419-44
HSL6235
Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L.
Financial ties between DSM-IV panel members and the pharmaceutical industry.
Psychother Psychosom 2006;75:(3):154-60
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=PPS2006075003154
HSL6245
Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ.
Influence of pharmacists' attitudes on adverse drug reaction reporting: a case-control study in Portugal.
Drug Saf 2006;29:(4):331-40
HSL6256
Belgers T.
[Reaction to 'About the comparison of public-private cooperation. Comment on Vandereycken']
Tijdschr Psychiatr 2006;48:(7):601-2
HSL6257
Buis WM.
[Reaction to 'Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry' and to 'The importance of public-private cooperation. Comment on Vandereycken']
Tijdschr Psychiatr. 2006;48:(6):500-1
HSL6261
Wolfe SM.
Schroeder Lecture Worst pills, best pills.
Health Matrix Clevel 2006 Sum;16:(2):785-96
HSL6314
Gillies R, Von Schon-Angerer, Hoen E.
Historic opportunity for WHO to re-assert leadership
The Lancet 2006;368:1405-1406
http://www.thelancet.com/
HSL6342
Oh R, Beresford S, Lafferty W.
The Fish in Secondary Prevention of Heart Disease (FISH) Survey--Primary Care Physicians and 3 Fatty Acid Prescribing Behaviors
J Am Board Fam Med. 2006;19:(5):459-467
http://www.medscape.com/viewarticle/545407
HSL6360
Blumsohn A
Authorship, ghost-science , access to data and control of the pharmaceutical scientific literature: Who stands to behind the word? The American Association for the Advancement of Science Proffesional Ethics Report
: The American Association for the Advancement of Science 2006
HSL6363
Joung W, Hesketh B, Neal A.
Using 'war stories' to train for adaptive performance: Is it better to learn from error or success?
Applied Psychology: An International Review 2006;55:282-302
HSL6367
Pauer-studer H.
Public Reason and Bioethics
Medscape General Medicine. 2006;8(4):13. 2006;8:(4):13
http://www.medscape.com/viewarticle/544483_print
HSL6382
Tonkin AL, Taverner D, Latte J, Doecke C.
The Effect of an Interactive Tutorial on the Prescribing Performance of Senior Medical Students
Med Educ. 2006;
HSL6384
Koren G, Oren D, Rouleau M, Carmeli D, Matsui D.
Comparison of verbal claims for natural health products made by health food stores staff versus pharmacists in Ontario, Canada.
Can J Clin Pharmacol 2006 Sum;13:(2):e251-6
http://www.cjcp.ca/pdf/CJCP_e251-256F_8.31.06.pdf
HSL6390
Kind P.
US FDA guidance: apropos of PROs.
Pharmacoeconomics 2006;24:(9):833-6
HSL6423
Mansfield PR, Lexchin J, Wen LS, Grandori L, McCoy CP, Hoffman JR, Ramos J, Jureidini JN.
Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations
PLoS Med 2006;3:(11):e451
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371%2Fjournal.pmed.0030451
HSL6424
Mansfield P.
Industry-Sponsored Research: A More Comprehensive Alternative.
PLoS Med 2006;3:(10):e463
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030463
HSL7011
Lenzer J.
NIH Secrets: Study Break
The New Republic 2006
https://ssl.tnr.com/p/docsub.mhtml?i=20061030&s=lenzer103006
HSL7065
Dillon A, Littlejohns P.
How much will Herceptin really cost?
BMJ 2006;333:1219
http://www.bmj.com/cgi/content/full/333/7580/1219
HSL7260
Teufel AT.
Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
J Contemp Health Law Policy 2006 Spr;22:(2):383-408
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=pubmed
HSL7264
Toledano Mayoral G, Salmeron Garcia A, Roman Marquez E, Cabeza Barrera J.
[Inappropriate commercial presentation of selected drugs and associated overcost]
Farm Hosp. 2006 May-Jun;30:(3):195-6
http://www.grupoaran.com/mrmUpdate/lecturaPDFfromXML.asp?IdArt=458140&TO=RVN&Eng=0
HSL7382
AMA (US)
Prescribing Data Information Center
: AMA (US) 2006?
http://www.ama-assn.org/ama/pub/category/12054.html
HSL7418
Farrell K.
Human experimentation in developing countries: improving international practices by identifying vulnerable populations and allocating fair benefits.
J Health Care Law Policy 2006;9:(1):136-61
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=pubmed
HSL7420
Koper M, Bubela T, Caulfield T, Boon H.
Media portrayal of conflicts of interest in herbal remedy clinical trials.
Health Law Rev 2006;15:(1):9-11
http://www.law.ualberta.ca/centres/hli/hl_review.html
HSL7423
Bloche MG.
Race, money and medicines.
J Law Med Ethics 2006 Fall;34:(3):555-8,
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1748-720X.2006.00069.x
HSL7433
Donohue J.
A history of drug advertising: the evolving roles of consumers and consumer protection.
Milbank Q 2006;84:(4):659-99
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1468-0009.2006.00464.x
HSL7449
Center for Policy Alternatives
Prescription Drug Marketing
Washington, DC: Center for Policy Alternatives 2006
http://www.stateaction.org/issues/issue.cfm/issue/PrescriptionDrugMarketing.xml
HSL7450
American Medical Association
Physician Characteristics and Distribution in the US, 2006
-: American Medical Association 2006
https://catalog.ama-assn.org/Catalog/product/product_detail.jsp?productId=prod240177?checkXwho=done#
HSL7491
Tam JW, Dennehy CE, Ko R, Tsourounis C.
Analysis of ephedra-free labeled dietary supplements sold in the San Francisco Bay area in 2003.
J Herb Pharmacother 2006;6:(2):1-19
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17182481&query_hl=2&itool=pubmed_docsum
HSL7501
Evans BJ.
What will it take to reap the clinical benefits of pharmacogenomics?
Food Drug Law J 2006;61:(4):753-94
HSL7502
Steinhauer EH.
Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
Food Drug Law J 2006;61:(4):679-700
HSL7503
Hall RF, Berlin RJ.
When you have a hammer everything looks like a nail: misapplication of the False Claims Act to off-label promotion.
Food Drug Law J 2006;61:(4):653-77
HSL7504
Vodra WW, Cortez NG, Korn DE.
The Food and Drug Administration's evolving regulation of press releases: limits and challenges.
Food Drug Law J 2006;61:(4):623-51
HSL7505
Dorfman HL, Quinn VM, Brophy EA.
Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Food Drug Law J 2006;61:(4):585-622
HSL7579
Kadusevicius E, Mikucionyte L, Maciulaitis R, Milvidaite I, Sveikata A.
Trends in the consumption of antidepressant drugs in Lithuania in 2002-2004.
Medicina (Kaunas) 2006;42:(12):1020-9
http://medicina.kmu.lt/0612/0612-09e.pdf
HSL7580
Kubesova H, Holik J, Weber P, Polcarova V, Matejovsky J, Mazalova K, Slapak J.
[Drug consumption and risks of polypharmacotherapy in elderly population]
Cas Lek Cesk. 2006;145:(9):708-11
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17091726&query_hl=32&itool=pubmed_docsum
HSL7684
Menon MK, Goodnight JM, Wayne RJ.
Assessing advertising content in a hospital advertising campaign: An application of Puto and Wells (1984) measure of informational and transformational advertising content.
J Hosp Mark Public Relations 2006;17:(1):27-44
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17062533&dopt=Abstract
HSL7716
James H, Handu SS, Al Khaja KA, Otoom S, Sequeira RP.
Evaluation of the knowledge, attitude and practice of self-medication among first-year medical students.
Med Princ Pract 2006;15:(4):270-5
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=MPP2006015004270
HSL7857
Jamtvedt G, Young JM, Kristoffersen DT, O’brien MA, Oxman AD.
Does telling people what they have been doing change what they do?: A systematic review of the effects of audit and feedback
Quality and Safety in Health Care 2006;15:(6):433-436
http://qshc.bmj.com/cgi/content/full/15/6/433
HSL7985
Bradford WD, Kleit AN.
Evaluating the welfare effects of drug advertising
Regulation 2006;29:(1 (Spring)):58-62
http://www.cato.org/pubs/regulation/regv29n1/v29n1-7.pdf
HSL8045
Boer H, Ter Huurne E, Taal E.
Effects of pictures and textual arguments in sun protection public service announcements.
Cancer Detect Prev 2006;30:(5):432-8
http://linkinghub.elsevier.com/retrieve/pii/S0361-090X(06)00090-0
HSL8047
Cahana A, Mauron A.
The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
J Anesth 2006;20:(4):348-51
http://www.springerlink.com/content/l72202g04770g2ru/
Page 119 of 206 pages ‹ First < 117 118 119 120 121 > Last ›
